HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction

Ablynx NV

Division of Sanofi
www.ablynx.com

Latest From Ablynx NV

Bookmark
  • Analysis

Investigating Big Pharma Licensing Trends

By Andrew McConaghie

AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.

Deals Market Intelligence
Bookmark
  • Analysis

AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker

By Andrew McConaghie

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.

Deals Commercial
Bookmark
  • Analysis

Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue

By Mandy Jackson

Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.

Financing Business Strategies
Bookmark
  • Interviews

Interview: Achilles Advances Armed With £100m

By Kevin Grogan

After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.

Financing ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Edwin Moses, PhD, CEO
    Wim Ottevaere, CFO
    Markus Ewert, PhD, CBO
    Robert K Zeldin, MD, CMO
    Heylen Johan, Chief Commerical Officer
    Robert Friesen, PhD, CSO
  • Contact Info
  • Ablynx NV
    Phone: (32) 9 262 00 00
    Technologiepark 21
    Ghent/Zwijnaarde, 9052
    Belgium
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By